Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

University Hospital Tuebingen14 enrolled

Overview

The purpose of this study is to compare the ability of pegfilgrastim vs. filgrastim to mobilize peripheral blood stem cells in patients with Non Hodgkin-lymphoma in an intraindividual study

Patients with Non Hodgkin-lymphoma undergoing stem cell mobilization for planned high-dose therapy will be treated with two cycles of chemotherapy (etoposide, ifosfamide, cisplatin, epirubicin), either followed by daily administration of filgrastim (first cycle) or pegfilgrastim (once after the second cycle). The number of circulating cluster of differentiation 34+ cells, colony-forming units and primitive progenitors will be analyzed at corresponding time points. Peripheral blood stem cells will be collected after the second cycle of chemotherapy by leukapheresis. After the second cycle, high-dose therapy with peripheral blood stem cell support will be administered (the protocol will be chosen according to the diagnosis, including total body irradiation-containing regimens).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Hodgkin Lymphoma

Interventions

pegfilgrastimDRUG

Single dose (6mg) one day after chemotherapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histological diagnosis of non-Hodgkin lymphoma * planned high-dose therapy with autologous stem cell transplantation * WHO performance status 0-2 * written consent Exclusion Criteria: * allergy against (peg)filgrastim * life expectancy \<3 months * other malignant diseases within the last 5 years * cardial insufficiency (\>= New York Heart Association II°) * uncontrolled infection * pregnancy, lactation * central nervous system lymphoma * Karnofsky score \<70%

Locations (1)

Dept. of Medicine 2, University of Tuebingen

Tübingen, Baden-Wurttemberg, Germany

Outcomes

Primary Outcomes

Hematopoietic recovery after autologous stem cell transplantation

Two cycles of conventional chemotherapy are given. Starting one day after the first cycle, filgrastim (5ug/kg bodyweight daily subcutaneously) is routinely administered to support neutrophil recovery. One day after the second cycle, a single dose of pegfilgrastim (6mg) is given to support neutrophil recovery and stem cell collection. Hematopoietic recovery (blood count) is monitored daily after high-dose therapy and autologous stem cell transplantation. Follow up assessments are performed 3-monthly for late graft failure

Time frame: 1-3 weeks after transplantation, follow up every 3 months (up to 2 years)

Secondary Outcomes

Intraindividual comparison of quantity/quality of circulating stem cells

Circulating stem cells are enumerated by flow cytometry and colony assays during filgrastim (intraindividual control) and pegfilgrastim-supported recovery from chemotherapy.

Time frame: before and during 3 weeks after conventional chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.